<DOC>
	<DOCNO>NCT00100048</DOCNO>
	<brief_summary>This study investigate safety efficacy investigational drug Human immunodeficiency virus ( HIV ) infect patient .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Investigational Drug HIV Infected Patients ( 0518-004 ) ( COMPLETED )</brief_title>
	<detailed_description>Participants complete 48 week original 48-week double-blind study invite continue two extension : MK0518-004-10 ( NCT00100048 ) , extend study 144 week , MK0518-004-20 ( NCT00100048 ) , extend study 240 week . Participants randomize MK0518 base study continue 400 mg MK0518 twice daily . Participants randomize efavirenz base study continue receive efavirenz dosage give base study . The dos open label tenofovir lamivudine continue unchanged .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Patient must HIV positive must receive less 7 day total antiretroviral therapy ( HIV relate therapy ) Extension Studies : First extension : Patient complete 48week base study Second extension : Patient complete first 144week extension study Less 18 year age Individuals currently test positive HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>